Sera PrognosticsNovember 4, 2021Sera Prognostics Announces Collaboration to Help Underserved Communities Make Informed Decision about Prenatal Health
PanTher TherapeuticsOctober 15, 2021PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
Sera PrognosticsSeptember 15, 2021Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
Sera PrognosticsAugust 17, 2021Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility
Catalyst Health VenturesAugust 11, 2021Meet Josh Phillips and Darshana Zaveri, Managing Partners at Catalyst Health Ventures
PanTher TherapeuticsAugust 4, 2021PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia; Announces Appointment of Chief Medical Officer; Establishes Clinical Advisory Board
PanTher TherapeuticsJune 17, 2021PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer
Sera PrognosticsMay 19, 2021Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk of Preterm Birth
Sera PrognosticsMay 18, 2021Evaluation of Health and Economic Benefit of the PreTRM® Test-And-Treat Strategy to Improve Maternal and Infant Health Among Commercially Insured in the US
